Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma.
Journal
Case reports in endocrinology
ISSN: 2090-6501
Titre abrégé: Case Rep Endocrinol
Pays: United States
ID NLM: 101576457
Informations de publication
Date de publication:
2019
2019
Historique:
received:
27
06
2019
accepted:
08
10
2019
entrez:
31
12
2019
pubmed:
31
12
2019
medline:
31
12
2019
Statut:
epublish
Résumé
Anaplastic thyroid carcinoma (ATC) is a deadly disease with very limited therapeutic options. There is an urgent need for new and efficacious drugs. Unfortunately accrual in clinical trials is problematic because of the rarity of the disease and often poor performance status at diagnosis. Recently some data have emerged suggesting a role for immunotherapy in the treatment of ATC. We describe the case of a 75-year-old patient with poor performance status and compromised airway and oesophagus at diagnosis, showing a rapid and dramatic response to first line single agent pembrolizumab. Disease progression in the brain occurred 16 months after initial diagnosis. At that time there was ongoing extracranial disease control.
Identifiants
pubmed: 31885948
doi: 10.1155/2019/9095753
pmc: PMC6899289
doi:
Types de publication
Case Reports
Langues
eng
Pagination
9095753Informations de copyright
Copyright © 2019 Valérie Spalart et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
J Oncol Pract. 2016 Jun;12(6):511-8
pubmed: 27288464
Front Oncol. 2017 Mar 01;7:25
pubmed: 28299283
J Clin Oncol. 2018 Jan 1;36(1):7-13
pubmed: 29072975
J Immunother Cancer. 2018 Jul 11;6(1):68
pubmed: 29996921
Oncologist. 2017 Oct;22(10):1149-1151
pubmed: 28778959
Endocrinol Metab Clin North Am. 2019 Mar;48(1):269-284
pubmed: 30717908